• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by MBX Biosciences Inc.

    11/10/25 5:08:55 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MBX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)


    MBX Biosciences, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    55287L101

    (CUSIP Number)


    Stephanie Brecher
    New Enterprise Associates, 1954 Greenspring Drive, Suite 600
    Timonium, MD, 21093
    (410)842-4000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    11/06/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    55287L101


    1 Name of reporting person

    New Enterprise Associates 17, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,614,486.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,614,486.00
    11Aggregate amount beneficially owned by each reporting person

    3,614,486.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.1 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    55287L101


    1 Name of reporting person

    NEA Partners 17, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,614,486.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,614,486.00
    11Aggregate amount beneficially owned by each reporting person

    3,614,486.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.1 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    55287L101


    1 Name of reporting person

    NEA 17 GP, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,614,486.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,614,486.00
    11Aggregate amount beneficially owned by each reporting person

    3,614,486.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.1 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    55287L101


    1 Name of reporting person

    Forest Baskett
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,614,486.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,614,486.00
    11Aggregate amount beneficially owned by each reporting person

    3,614,486.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    55287L101


    1 Name of reporting person

    Ali Behbahani
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,614,486.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,614,486.00
    11Aggregate amount beneficially owned by each reporting person

    3,614,486.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    55287L101


    1 Name of reporting person

    Carmen Chang
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,614,486.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,614,486.00
    11Aggregate amount beneficially owned by each reporting person

    3,614,486.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    55287L101


    1 Name of reporting person

    Anthony A. Florence, Jr.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,614,486.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,614,486.00
    11Aggregate amount beneficially owned by each reporting person

    3,614,486.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    55287L101


    1 Name of reporting person

    Mohamad H. Makhzoumi
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,614,486.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,614,486.00
    11Aggregate amount beneficially owned by each reporting person

    3,614,486.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    55287L101


    1 Name of reporting person

    Edward T. Mathers
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    4,988.00
    8Shared Voting Power

    3,614,486.00
    9Sole Dispositive Power

    4,988.00
    10Shared Dispositive Power

    3,614,486.00
    11Aggregate amount beneficially owned by each reporting person

    3,619,474.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    55287L101


    1 Name of reporting person

    Scott D. Sandell
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,614,486.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,614,486.00
    11Aggregate amount beneficially owned by each reporting person

    3,614,486.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    55287L101


    1 Name of reporting person

    Paul Walker
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,614,486.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,614,486.00
    11Aggregate amount beneficially owned by each reporting person

    3,614,486.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    55287L101


    1 Name of reporting person

    Rick Yang
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,614,486.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,614,486.00
    11Aggregate amount beneficially owned by each reporting person

    3,614,486.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.0001 per share
    (b)Name of Issuer:

    MBX Biosciences, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    11711 N. Meridian Street, Suite 300, Carmel, INDIANA , 46032.
    Item 1 Comment:
    This Amendment No. 1 ("Amendment No. 1") to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on September 23, 2024 (the "Schedule 13D") relating to the Common Stock of the Issuer. Certain terms used but not defined in this Amendment No. 1 have the meanings assigned thereto in the Schedule 13D. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported on the Schedule 13D. This Amendment No. 1 is being filed to report that the beneficial ownership of Common Stock by the Reporting Persons (as defined below) has decreased by more than 1% as a result of an increase in the number of Common Stock outstanding.
    Item 2.Identity and Background
    (a)
    New Enterprise Associates 17, L.P. ("NEA 17"); NEA Partners 17, L.P. ("NEA Partners 17"), which is the sole general partner of NEA 17; and NEA 17 GP, LLC ("NEA 17 LLC" and, together with NEA Partners 17, the "Control Entities"), which is the sole general partner of NEA Partners 17; and Forest Baskett ("Baskett"), Ali Behbahani ("Behbahani"), Carmen Chang ("Chang"), Anthony A. Florence, Jr. ("Florence"), Mohamad H. Makhzoumi ("Makhzoumi"), Edward T. Mathers ("Mathers"), Scott D. Sandell ("Sandell"), Paul Walker ("Walker"), and Rick Yang ("Yang") (together, the "Managers"). The Managers are the managers of NEA 17 LLC. The persons named in this Item 2 are referred to individually herein as "Reporting Person" and collectively as the "Reporting Persons."
    (b)
    The address of the principal business office of NEA 17, each Control Entity and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett, Behbahani, Chang, Makhzoumi, Walker and Yang is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, CA 94025. The address of the principal business office of Florence and Mathers is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10011.
    (c)
    The principal business of NEA 17 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 17 is to act as the sole general partner of NEA 17. The principal business of NEA 17 LLC is to act as the sole general partner of NEA Partners 17. The principal business of each of the Managers is to manage the Control Entities, NEA 17 and a number of affiliated partnerships with similar businesses.
    (d)
    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (e)
    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    NEA 17 LLC is a limited liability company organized under the laws of the State of Delaware. NEA 17 and NEA Partners 17 are limited partnerships organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Not applicable.
    Item 4.Purpose of Transaction
     
    NEA 17 acquired the NEA 17 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 17 and the other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) Any action similar to any of those enumerated above.
    Item 5.Interest in Securities of the Issuer
    (a)
    NEA 17 is the record owner of the NEA 17 Shares. As the general partner of NEA 17, NEA Partners 17 may be deemed to own beneficially the NEA 17 Shares. As the sole general partner of NEA Partners 17, NEA 17 LLC may be deemed to beneficially own the NEA 17 Shares. As members of NEA 17 LLC each of the Managers may be deemed to own beneficially the NEA 17 Shares. Each Reporting Person disclaims beneficially ownership of the NEA 17 Shares other than those shares which such person owns of record. As of November 10, 2025, Mathers is the record owner of options to purchase 4,988 shares of Common Stock (the "Mathers Option Shares"), exercisable within 60 days. The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Peron's cover sheet. Such percentage was calculated based on 44,902,302 shares of Common Stock reported by the Issuer to be outstanding as of November 3, 2025 on the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025. The percentage set forth on the cover sheet for Mathers is calculated based on the shares described in the preceding sentence plus the Mathers Option Shares.
    (b)
    Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets (ii) shared power to vote or to direct the vote: See line 8 of cover sheets (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.
    (c)
    None of the Reporting Persons have effected any transaction in the last 60 days.
    (d)
    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Common Stock beneficially owned by any of the Reporting Persons.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Not applicable.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 1 - Agreement regarding filing of joint Schedule 13D. Exhibit 2 - Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    New Enterprise Associates 17, L.P.
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
    Date:11/10/2025
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
    Date:11/10/2025
     
    NEA Partners 17, L.P.
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
    Date:11/10/2025
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
    Date:11/10/2025
     
    NEA 17 GP, LLC
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
    Date:11/10/2025
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
    Date:11/10/2025
     
    Forest Baskett
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Forest Baskett
    Date:11/10/2025
     
    Ali Behbahani
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Ali Behbahani
    Date:11/10/2025
     
    Carmen Chang
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Carmen Chang
    Date:11/10/2025
     
    Anthony A. Florence, Jr.
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr.
    Date:11/10/2025
     
    Mohamad H. Makhzoumi
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi
    Date:11/10/2025
     
    Edward T. Mathers
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Edward T. Mathers
    Date:11/10/2025
     
    Scott D. Sandell
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Scott D. Sandell
    Date:11/10/2025
     
    Paul Walker
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Paul Walker
    Date:11/10/2025
     
    Rick Yang
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Rick Yang
    Date:11/10/2025
    Comments accompanying signature:
    This Amendment No. 1 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.
    Get the next $MBX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MBX

    DatePrice TargetRatingAnalyst
    12/4/2025$18.00Sell
    Goldman
    11/4/2025Buy
    TD Cowen
    10/15/2025$50.00Buy
    Truist
    8/15/2025$36.00Buy
    Jefferies
    8/5/2025$38.00Outperform
    Mizuho
    7/16/2025$38.00Outperform
    Oppenheimer
    4/10/2025$38.00Mkt Outperform
    Citizens JMP
    10/8/2024$44.00Buy
    Guggenheim
    More analyst ratings

    $MBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hoerter Steven L.

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    11/25/25 8:50:28 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hoerter Steven L.

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    11/7/25 8:20:09 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Hawryluk P. Kent exercised 182,859 shares at a strike of $3.25, increasing direct ownership by 38% to 664,256 units (SEC Form 4)

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    10/28/25 8:03:15 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on MBX Biosciences with a new price target

    Goldman initiated coverage of MBX Biosciences with a rating of Sell and set a new price target of $18.00

    12/4/25 8:45:53 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on MBX Biosciences

    TD Cowen initiated coverage of MBX Biosciences with a rating of Buy

    11/4/25 7:44:06 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on MBX Biosciences with a new price target

    Truist initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $50.00

    10/15/25 8:30:22 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Hawryluk P. Kent bought $272,790 worth of shares (20,000 units at $13.64) (SEC Form 4)

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    10/21/25 5:43:44 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoerter Steven L. bought $264,984 worth of shares (20,000 units at $13.25) (SEC Form 4)

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    10/20/25 4:44:37 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Patrick J bought $11,999,988 worth of shares (666,666 units at $18.00) (SEC Form 4)

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    9/30/25 4:59:56 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference

    CARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present and participate in the 37th Annual Piper Sandler Healthcare Conference being held on December 2-4. 37th Annual Piper Sandler Healthcare Conference Date: Tuesday, December 2, 2025Format: Fireside chat and 1x1 meetingsTime: 4:00 p.m. – 4:25 p.m. ETLocation: New York, NY The live webcast can be accesse

    11/18/25 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

    Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising approximately $200 million in gross proceeds $391.7 million in cash, cash equivalents and marketable securities as of September 30, 2025; expected to support operations into 2029 Updated 2026 corporate milestones include clinical data for three Precision Endocrine Peptide™ (PEP) programs and initiation of a Phase 3 trial in HP CARMEL, Ind., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therap

    11/6/25 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences to Participate in November Investor Conferences

    CARMEL, Ind., Oct. 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at and participate in the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference Date: Monday, November 10, 2025Format: Fireside chat and 1x1 meetingsTime: 3:30 p.m. – 3:55 p.m. ETLocation: Boston, MA Stifel Healthcare Conference Date: Wednesday, November 12

    10/20/25 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    SEC Filings

    View All

    SEC Form EFFECT filed by MBX Biosciences Inc.

    EFFECT - MBX Biosciences, Inc. (0001776111) (Filer)

    12/9/25 12:15:32 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by MBX Biosciences Inc.

    SCHEDULE 13G/A - MBX Biosciences, Inc. (0001776111) (Subject)

    11/14/25 4:05:45 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by MBX Biosciences Inc.

    SCHEDULE 13D/A - MBX Biosciences, Inc. (0001776111) (Subject)

    11/10/25 5:08:55 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Leadership Updates

    Live Leadership Updates

    View All

    MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

    CARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Andreas Moraitis, M.D., as Senior Vice President of Clinical Development. "Canvuparatide has the potential to provide a meaningful new option for people living with hypoparathyroidism, an area where patients continue to face significant unmet needs," said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. "Andreas' deep expertise in endocrinology and proven track record of lea

    6/23/25 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

    Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate

    5/12/25 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors

    CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company's Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical commercialization and executive leadership experience as well as a proven track record of building and growing life science companies. "I am thrilled to welcome Steve Hoerter to the Company's Board as an independent director," said Kent Hawryluk, President and Chief

    4/7/25 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Financials

    Live finance-specific insights

    View All

    MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

    Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE) Positive findings in bone and kidney biomarkers All patients completed the 12-week AvailTM trial and 94% entered the OLE Once-weekly canvuparatide was generally well tolerated, with no treatment-related serious adverse events or discontinuations during the 12-week trial Preparation underway to initiate Phase 3 trial in 2026 Company to host conference call at 8:00 am ET today CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on

    9/22/25 7:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

    CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism (HP) and host an investor webcast on Monday, September 22. The Company will host a conference call and webcast at 8 am ET on Monday, September 22 to discuss the results from the Avail™ Phase 2 trial. Those who would like to participate may access the live webcast he

    9/19/25 4:18:59 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

    Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing Company to host conference call to discuss results today at 8:30 am ET CARMEL, Ind., Jan. 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today annou

    1/7/25 7:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by MBX Biosciences Inc.

    SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

    11/8/24 10:52:39 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by MBX Biosciences Inc.

    SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

    11/1/24 5:38:56 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by MBX Biosciences Inc.

    SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)

    9/23/24 6:07:21 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care